Literature DB >> 33363024

A Nomogram Based on Serum Biomarkers and Clinical Characteristics to Predict Survival in Patients With Non-Metastatic Nasopharyngeal Carcinoma.

Qing-Jie Li1, Yan-Ping Mao1, Rui Guo1, Cheng-Long Huang1, Xue-Liang Fang1, Jun Ma1, Ling-Long Tang1, Lei Chen1.   

Abstract

OBJECTIVE: This study focused on developing an effective nomogram for improving prognostication for patients with primary nasopharyngeal carcinoma (NPC) restaged according to the eighth edition of the AJCC/UICC TNM staging system.
METHODS: Based on data of 5,903 patients with non-metastatic NPC (primary cohort), we used Cox regression analysis to identify survival risk factors and created a nomogram. We used the nomogram to predict overall survival (OS), distant metastasis-free survival (DMFS) and disease-free survival (DFS) in the primary and independent validation (3,437 patients) cohorts. Moreover, we compared the prognostic accuracy between the 8th TNM system and the nomogram.
RESULTS: The nomogram included gender, age, T stage, N stage, Epstein-Barr virus DNA, hemoglobin, C-reactive protein, lactate dehydrogenase, and radiotherapy with/without induction or concurrent chemotherapy. In the prediction of OS, DMFS and DFS, the nomogram had significantly higher concordance index (C-index) and area under ROC curve (AUC) than the TNM system alone. Calibration curves demonstrated satisfactory agreements between nomogram-predicted and observed survival. The stratification in different groups permitted remarkable differentiation among Kaplan-Meier curves for OS, DMFS, and DFS.
CONCLUSION: The nomogram led to a more precise prognostic prediction for NPC patients in comparison with the 8th TNM system. Therefore, it could facilitate individualized and personalized patients' counseling and care.
Copyright © 2020 Li, Mao, Guo, Huang, Fang, Ma, Tang and Chen.

Entities:  

Keywords:  nasopharyngeal carcinoma; nomogram; prognostic prediction; serum biomarkers; survival

Year:  2020        PMID: 33363024      PMCID: PMC7758498          DOI: 10.3389/fonc.2020.594363

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  31 in total

Review 1.  Focus on nasopharyngeal carcinoma.

Authors:  Kwok Wai Lo; Ka Fai To; Dolly P Huang
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

2.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Anthony T C Chan; S F Leung; Roger K C Ngan; Peter M L Teo; W H Lau; W H Kwan; Edwin P Hui; H Y Yiu; Winnie Yeo; F Y Cheung; K H Yu; K W Chiu; D T Chan; Tony S K Mok; Stephen Yau; K T Yuen; Frankie K F Mo; Maria M P Lai; Brigette B Y Ma; Michael K M Kam; Thomas W T Leung; Philip J Johnson; Peter H K Choi; Benny C Y Zee
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

3.  Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution.

Authors:  H Chang; J Gao; B Q Xu; S P Guo; R B Lu; G Li; S M Huang; F Han; Z G Liu; Y L Tao; Z W Tu; C Chen; X H Li; Y F Xia
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-07-31       Impact factor: 4.126

4.  Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma.

Authors:  Xue-Song Sun; Yu-Jing Liang; Sai-Lan Liu; Xiao-Yun Li; Qiu-Yan Chen; Shan-Shan Guo; Yue-Feng Wen; Li-Ting Liu; Hao-Jun Xie; Qing-Nan Tang; Jin-Jie Yan; Ling Guo; Jun Ma; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Oral Oncol       Date:  2019-05-22       Impact factor: 5.337

5.  Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution.

Authors:  Guo Li; Jin Gao; Zhi-Gang Liu; Ya-Lan Tao; Bing-Qing Xu; Zi-Wei Tu; Xiu-Ping Zhang; Mu-Sheng Zeng; Yun-Fei Xia
Journal:  Head Neck       Date:  2013-07-30       Impact factor: 3.147

6.  Involvement of difference in decrease of hemoglobin level in poor prognosis of Stage I and II nasopharyngeal carcinoma: implication in outcome of radiotherapy.

Authors:  Jin Gao; Ya-Lan Tao; Guo Li; Wei Yi; Yun-Fei Xia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-25       Impact factor: 7.038

7.  Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.

Authors:  A T C Chan; P M L Teo; R K Ngan; T W Leung; W H Lau; B Zee; S F Leung; F Y Cheung; W Yeo; H H Yiu; K H Yu; K W Chiu; D T Chan; T Mok; K T Yuen; F Mo; M Lai; W H Kwan; P Choi; P J Johnson
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

8.  Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival.

Authors:  Hai-Yun Wang; Bing-Yu Sun; Zhi-Hua Zhu; Ellen T Chang; Ka-Fai To; Jacqueline S G Hwang; Hao Jiang; Michael Koon-Ming Kam; Gang Chen; Shie-Lee Cheah; Ming Lee; Zhi-Wei Liu; Jing Chen; Jia-Xing Zhang; Hui-Zhong Zhang; Jie-Hua He; Fa-Long Chen; Xiao-Dong Zhu; Ma-Yan Huang; Ding-Zhun Liao; Jia Fu; Qiong Shao; Man-Bo Cai; Zi-Ming Du; Li-Xu Yan; Chun-Fang Hu; Ho-Keung Ng; Joseph T S Wee; Chao-Nan Qian; Qing Liu; Ingemar Ernberg; Weimin Ye; Hans-Olov Adami; Anthony T Chan; Yi-Xin Zeng; Jian-Yong Shao
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

9.  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Authors:  Li Zhang; Yan Huang; Shaodong Hong; Yunpeng Yang; Gengsheng Yu; Jun Jia; Peijian Peng; Xuan Wu; Qing Lin; Xuping Xi; Jiewen Peng; Mingjun Xu; Dongping Chen; Xiaojun Lu; Rensheng Wang; Xiaolong Cao; Xiaozhong Chen; Zhixiong Lin; Jianping Xiong; Qin Lin; Conghua Xie; Zhihua Li; Jianji Pan; Jingao Li; Shixiu Wu; Yingni Lian; Quanlie Yang; Chong Zhao
Journal:  Lancet       Date:  2016-08-23       Impact factor: 79.321

Review 10.  Epstein-Barr virus infection and nasopharyngeal carcinoma.

Authors:  Sai Wah Tsao; Chi Man Tsang; Kwok Wai Lo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

View more
  5 in total

1.  Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.

Authors:  Chao Deng; Na Zhang; Shun Jiang; Haixia Zhang; Jin'an Ma; Wen Zou; Xianling Liu; Chunhong Hu; Tao Hou
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Huiyun Yang; Rongjun Zhang; Ruyun Zhang; Bin Zhang; Yuan Xie; Guanjie Qin; Yunyan Mo; Xiaolan Ruan; Wei Jiang
Journal:  Strahlenther Onkol       Date:  2022-04-06       Impact factor: 4.033

3.  LncRNA FOXD3-AS1 Promotes the Malignant Progression of Nasopharyngeal Carcinoma Through Enhancing the Transcription of YBX1 by H3K27Ac Modification.

Authors:  Huiyun Yang; Yuliang Pan; Jun Zhang; Long Jin; Xi Zhang
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

4.  Assessment of Metastatic Colorectal Cancer (CRC) Tissues for Interpreting Genetic Data in Forensic Science by Applying 16 STR Loci among Saudi Patients.

Authors:  Wedad Saeed Al-Qahtani; Tahani Mohamed Al-Hazani; Fatmah Ahmed Safhi; Mashael Alhumaidi Alotaibi; Dalia Mostafa Domiaty; Salha M S Al-Shamrani; Eman Alshehri; Amani Mohammed Alotaibi; Saad Alkahtani
Journal:  Asian Pac J Cancer Prev       Date:  2021-09-01

5.  Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load.

Authors:  Yu-Ting Jiang; Kai-Hua Chen; Jie Yang; Zhong-Guo Liang; Song Qu; Ling Li; Xiao-Dong Zhu
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.